Nurix Therapeutics (NRIX) Operating Income: 2019-2025
Historic Operating Income for Nurix Therapeutics (NRIX) over the last 6 years, with Aug 2025 value amounting to -$91.4 million.
- Nurix Therapeutics' Operating Income fell 67.34% to -$91.4 million in Q3 2025 from the same period last year, while for Aug 2025 it was -$267.2 million, marking a year-over-year decrease of 37.96%. This contributed to the annual value of -$213.0 million for FY2024, which is 37.38% down from last year.
- Per Nurix Therapeutics' latest filing, its Operating Income stood at -$91.4 million for Q3 2025, which was down 89.12% from -$48.3 million recorded in Q2 2025.
- In the past 5 years, Nurix Therapeutics' Operating Income ranged from a high of -$24.5 million in Q1 2021 and a low of -$91.4 million during Q3 2025.
- Over the past 3 years, Nurix Therapeutics' median Operating Income value was -$48.3 million (recorded in 2025), while the average stood at -$51.9 million.
- As far as peak fluctuations go, Nurix Therapeutics' Operating Income plummeted by 99.65% in 2021, and later soared by 41.45% in 2023.
- Over the past 5 years, Nurix Therapeutics' Operating Income (Quarterly) stood at -$38.0 million in 2021, then dropped by 28.29% to -$48.7 million in 2022, then rose by 6.89% to -$45.3 million in 2023, then crashed by 42.62% to -$64.7 million in 2024, then tumbled by 67.34% to -$91.4 million in 2025.
- Its last three reported values are -$91.4 million in Q3 2025, -$48.3 million for Q2 2025, and -$62.9 million during Q1 2025.